UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Stock Holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 116,317 shares of the biopharmaceutical company's stock after acquiring an additional 13,722 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.18% of Celldex Therapeutics worth $2,939,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Values First Advisors Inc. increased its stake in Celldex Therapeutics by 20.0% during the 4th quarter. Values First Advisors Inc. now owns 29,009 shares of the biopharmaceutical company's stock worth $733,000 after buying an additional 4,837 shares during the period. Barclays PLC grew its stake in shares of Celldex Therapeutics by 140.7% in the third quarter. Barclays PLC now owns 130,381 shares of the biopharmaceutical company's stock worth $4,431,000 after acquiring an additional 76,207 shares in the last quarter. Invesco Ltd. grew its stake in shares of Celldex Therapeutics by 2.1% in the fourth quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after acquiring an additional 871 shares in the last quarter. Sovran Advisors LLC acquired a new stake in shares of Celldex Therapeutics in the fourth quarter valued at $2,867,000. Finally, Swiss National Bank raised its stake in shares of Celldex Therapeutics by 1.2% in the fourth quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock valued at $2,964,000 after acquiring an additional 1,400 shares in the last quarter.

Celldex Therapeutics Stock Performance

Celldex Therapeutics stock traded down $0.64 during midday trading on Monday, hitting $20.71. 851,199 shares of the company's stock were exchanged, compared to its average volume of 918,377. The firm's 50 day simple moving average is $18.98 and its 200 day simple moving average is $21.95. Celldex Therapeutics, Inc. has a 12-month low of $14.40 and a 12-month high of $47.00. The stock has a market cap of $1.37 billion, a price-to-earnings ratio of -8.06 and a beta of 1.33.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. The company had revenue of $0.70 million during the quarter, compared to analyst estimates of $1.08 million. On average, equities research analysts forecast that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have weighed in on CLDX shares. The Goldman Sachs Group cut their price target on Celldex Therapeutics from $36.00 to $31.00 and set a "neutral" rating on the stock in a report on Friday, May 9th. Morgan Stanley lowered their price objective on Celldex Therapeutics from $46.00 to $43.00 and set an "overweight" rating for the company in a research report on Friday, May 9th. HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Celldex Therapeutics in a research note on Tuesday, May 6th. UBS Group decreased their price target on shares of Celldex Therapeutics from $44.00 to $38.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Finally, Canaccord Genuity Group initiated coverage on shares of Celldex Therapeutics in a research report on Monday, April 28th. They issued a "buy" rating and a $64.00 price objective on the stock. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Celldex Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $53.90.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.